Author:
Hill Joshua A.,Martens Michael J.,Young Jo-Anne H.,Bhavsar Kavita,Kou Jianqun,Chen Min,Lee Lik Wee,Baluch Aliyah,Dhodapkar Madhav V.,Nakamura Ryotaro,Peyton Kristin,Howard Dianna S.,Ibrahim Uroosa,Shahid Zainab,Armistead Paul,Westervelt Peter,McCarty John,McGuirk Joseph,Hamadani Mehdi,DeWolf Susan,Hosszu Kinga,Sharon Elad,Spahn Ashley,Toor Amir A.,Waldvogel Stephanie,Greenberger Lee M.,Auletta Jeffery J.,Horowitz Mary M.,Riches Marcie L.,Perales Miguel-Angel
Abstract
ABSTRACTBackgroundThe optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood.ObjectiveTo describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy.DesignMulticenter prospective observational study.Setting34 centers in the United States.Participants466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022.InterventionsSARS-CoV-2 vaccination as part of routine care.MeasurementsWe obtained blood prior to and after vaccinations at up to five time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2-specific T cell receptors (TCRs), in a subgroup.ResultsAnti-S IgG and neutralizing antibody responses increased with vaccination in HCT recipients irrespective of vaccine initiation timing but were unchanged in CAR-T cell recipients initiating vaccines within 4 months. Anti-S IgG ≥2,500 U/mL was correlated with high neutralizing antibody titers and attained by the last time point in 70%, 69%, and 34% of allogeneic HCT, autologous HCT, and CAR-T cell recipients, respectively. SARS-CoV-2-specific T cell responses were attained in 57%, 83%, and 58%, respectively. Humoral and cellular responses did not significantly differ among participants initiating vaccinations <4 months vs 4-12 months after cellular therapy. Pre-cellular therapy SARS-CoV-2 infection or vaccination were key predictors of post-cellular therapy anti-S IgG levels.LimitationsThe majority of participants were adults and received mRNA vaccines.ConclusionsThese data support starting mRNA SARS-CoV-2 vaccination three to four months after allogeneic HCT, autologous HCT, and CAR-T cell therapy.FundingNational Marrow Donor Program, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Novartis, LabCorp, American Society for Transplantation and Cellular Therapy, Adaptive Biotechnologies, and the National Institutes of Health
Publisher
Cold Spring Harbor Laboratory